Abstract: Application of a composition of FBP and a blood concentration stabilizer thereof in manufacturing medicaments for preventing and treating metabolic diseases and metabolic dysfunction related diseases. The FBP may also be a pharmaceutically acceptable salt or hydrate of prototype thereof, a prodrug thereof, or a derivative thereof. The blood concentration stabilizer refers to a medicament or substance for treating diabetes capable of slowing down rapid in vivo degradation of FBP in a pharmaceutical preparation. The composition can cause a higher FBP blood concentration peak value and a more stable blood concentration, and can reduce an FBP dosage and thus can reduce the toxicity resulted from a large amount of inorganic phosphorus entering systemic circulation after degradation of a large dosage of FBP.

Abstract: The present invention provides a martensitic stainless steel and manufacturing process therefor, the mass ratio of chemical elements of the stainless steel is C: 0.01˜0.18 wt %, Si: 0.4˜1.5 wt %; Mn: 0.4˜3.0 wt %, P: ?0.04 wt %, S: 0.002˜0.01 wt %, Cr: 11.0˜15.0 wt %, N: 0.01˜0.15 wt %, Nb: 0.001˜0.01 wt %, V: 0.05˜0.25 wt %, Ti: 0.001˜0.01 wt %, Mo: 0.01˜1.50 wt %, B: 0.0005˜0.001 wt %, and balance being Fe and other unavoidable impurities. Further, the present invention provides a method for producing a martensitic stainless steel. The martensitic stainless steel of this present patent has a high hardness and high toughness and has excellent high-temperature oxidation resistance.